Leerink Partners and Jefferies Financial Group issue ratings for Latigo Biotherapeutics
2 reports, 1 independent
Updated Thu 00:00
No new developments lately
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Latigo Biotherapeutics appointed Todd Smith as CEO. Leerink Partners and Jefferies Financial Group issued ratings on the company, which recently reported ($0.55) EPS for the quarter. On Thursday, the company's stock traded down 7.3%.
From dailypolitical.com
Why it matters
The ratings from Leerink Partners and Jefferies Financial Group, along with the appointment of a new CEO, influence investment sentiment and market valuation for Latigo Biotherapeutics.
From dailypolitical.com
Who's involved
- Leerink partnersIssued an 'outperform' rating and a $36.00 target price for the company.
- Jefferies Financial GroupIssued a 'buy' rating and a $50.00 target price for the company.
Keep exploring
The entities involved
-
Leerink partners
U.S. investment bank
-
Jefferies Financial Group
American financial services company